Entera Bio (ENTX) financial statements
Entera Bio reported revenue of $42,000 in fiscal 2025, down 29.8% a year over 7 years.
Net income was -$11M.
Free cash flow was -$7M.
The diluted share count rose 584% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Entera Bio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $500,000 | $236,000 | $365,000 | $571,000 | $134,000 | $0 | $181,000 | $42,000 |
| Cost of revenue | — | — | — | $210,000 | $300,000 | $373,000 | $101,000 | $0 | $172,000 | $42,000 |
| Gross profit | — | — | — | — | $65,000 | $198,000 | $33,000 | $0 | $9,000 | $0 |
| Research and development | $3M | $3M | $9M | $7M | $6M | $7M | $6M | $5M | $4M | $6M |
| Selling, general and admin | $3M | $9M | $3M | $4M | $5M | $6M | $7M | $4M | $340,000 | $398,000 |
| Operating income | -$5M | -$11M | -$11M | -$11M | -$11M | -$12M | -$13M | -$9M | -$10M | -$12M |
| Pre-tax income | — | — | -$10M | -$11M | -$11M | -$12M | -$13M | -$9M | -$10M | -$11M |
| Income tax | — | — | — | — | $20,000 | -$59,000 | $137,000 | $29,000 | $14,000 | $0 |
| Net income | -$1M | -$11M | -$10M | -$11M | -$11M | -$12M | -$13M | -$9M | -$10M | -$11M |
| EPS (diluted) | $0.78 | $2.49 | $1.31 | $0.89 | $0.67 | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Diluted shares | 7M | 4M | 8M | 12M | 18M | 26M | 29M | 29M | 38M | 46M |
| Gross margin | — | — | — | — | 17.8% | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating margin | — | — | -2172.2% | -4853.4% | -3059.7% | -2139.6% | -9714.2% | — | -5295.6% | -27450.0% |
| Net margin | — | — | -2060.8% | -4574.2% | -3072.9% | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
Balance sheet
Fiscal years, from Entera Bio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $4M | $12M | $8M | $15M | $9M | $25M | $12M | $11M | $9M | $7M |
| Receivables | — | — | $725,000 | $278,000 | $255,000 | $183,000 | $246,000 | $0 | $126,000 | $0 |
| Total current assets | — | $12M | $12M | $16M | $9M | $25M | $13M | $11M | $9M | $15M |
| Property, plant and equipment | — | $207,000 | $224,000 | $202,000 | $192,000 | $156,000 | $139,000 | $100,000 | $57,000 | $134,000 |
| Total assets | — | $13M | $13M | $17M | $10M | $26M | $13M | $12M | $9M | $16M |
| Total current liabilities | — | $2M | $3M | $5M | $2M | $3M | $1M | $1M | $1M | $2M |
| Long-term debt | — | $4M | — | — | — | — | — | — | — | — |
| Total liabilities | — | $45M | $3M | $5M | $2M | $3M | $1M | $1M | $1M | $3M |
| Shareholders' equity | -$25M | -$32M | $10M | $12M | $8M | $23M | $12M | $10M | $8M | $13M |
| Net debt | -$4M | -$8M | -$8M | -$15M | -$9M | -$25M | -$12M | -$11M | -$9M | -$7M |
Cash flow
Fiscal years, from Entera Bio's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3M | -$5M | -$10M | -$9M | -$11M | -$9M | -$12M | -$7M | -$7M | -$7M |
| Capital spending | $41,000 | $51,000 | $68,000 | $40,000 | $53,000 | $17,000 | $47,000 | $17,000 | $3,000 | $107,000 |
| Free cash flow | -$3M | -$5M | -$10M | -$9M | -$11M | -$9M | -$13M | -$7M | -$7M | -$7M |
| Stock-based compensation | $1M | $5M | $1M | $1M | $901,000 | $2M | $2M | $2M | $3M | $3M |
| Net borrowing | $7M | -$980,000 | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | -1972.8% | -3796.2% | -2906.8% | -1590.2% | -9362.7% | — | -3768.5% | -17802.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ENTX.
Open ENTX in InvestinglyQuestions
What was Entera Bio's revenue in 2025?
$42,000 in fiscal 2025, from its 10-K filing.
How much free cash flow does Entera Bio generate?
-$7M in fiscal 2025 (operating cash flow minus capital spending).
From Entera Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.